Medication info

Uni-ibandronate Injection (Ibandronic Acid Sodium Hydrate)

Prescription medicationInjectionsIntravenous injection
Ingredient · strength
Ibandronate Sodium Monohydrate›3.375mg / 1 prefilled syringe
Manufacturer / importer
Korea Union Pharmaceutical Co., Ltd.
Appearance
An injection in a colorless, transparent solution contained in a colorless, transparent glass prefilled syringe, accompanied by a single-use needle.
Packaging
3ml x 1 vial
Approval status
Active

MFDS item code 201903515 · Notified 2019.05.29 · Insurance code 665507451

Summary

Main use
Treatment of osteoporosis in postmenopausal women
Who receives it
Adults · Children
Adult administration
Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D as adjunctive supplements. If a scheduled dose is missed, administer the injection as soon as possible, then continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary for patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or less or whose creatinine clearance is 30ml/min or greater. Administration of this medicine is not recommended for patients whose serum creatinine is greater than 200 µmol/L(2.3mg/dL) or whose creatinine clearance is less than 30ml/min, because clinical experience in these patients is insufficient. Elderly patients No dose adjustment is necessary.
Child administration
The efficacy and safety of this medicine have not been studied in children 18 years of age or younger.

Ingredients

Manufacturer
Korea Union Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of osteoporosis in postmenopausal women

  • Osteoporosis
View approved original text

Postmenopausal osteoporosis is a condition where bones become weak and fracture risk increases due to decreased bone density. This medication helps strengthen bones, increase bone density, and prevent fractures. It is especially used to treat osteoporosis, which frequently occurs in women after menopause.

How it is given

Adult administration

Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D as adjunctive supplements. If a scheduled dose is missed, administer the injection as soon as possible, then continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary for patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or less or whose creatinine clearance is 30ml/min or greater. Administration of this medicine is not recommended for patients whose serum creatinine is greater than 200 µmol/L(2.3mg/dL) or whose creatinine clearance is less than 30ml/min, because clinical experience in these patients is insufficient. Elderly patients No dose adjustment is necessary.

Child administration

The efficacy and safety of this medicine have not been studied in children 18 years of age or younger.

Precautions

This medication must be administered only via intravenous injection; incorrect administration into arteries or near veins can cause tissue damage, so utmost caution is necessary. Patients with allergies to this medication or its ingredients, or those with untreated hypocalcemia should not use it. During treatment with this medication, gastrointestinal symptoms such as gastritis, diarrhea, abdominal pain, indigestion, nausea, and constipation may occur, as well as symptoms such as muscle pain, joint pain, headache, and rash. In some patients, flu-like symptoms, including fever, chills, fatigue, muscle pain, and joint pain, may temporarily occur, but they are usually mild and resolve naturally. Rarely, jaw or ear region osteonecrosis may occur in patients using this medication, so it is important for cancer patients or those receiving steroid or chemotherapy to consult a dentist and maintain good oral hygiene before administration. If dental treatment is needed, it is advisable to avoid excessive procedures during the use of this medication and consult a specialist to plan treatment if necessary. Severe bone, joint, or muscle pain may occur during treatment for osteoporosis with this medication; if such symptoms appear, immediate consultation with medical personnel is required. Long-term use of this medication may present a risk of atypical fractures in the femur or other bones, so any pain in the thigh or groin must be investigated. Women who are pregnant or breastfeeding should avoid this medication as its safety has not been established, particularly since harmful effects on the fetus have been observed in animal studies. This medication is excreted through the kidneys, so patients with impaired kidney function need regular examinations and careful monitoring. In cases of overdose, hypocalcemia and hypophosphatemia may occur, necessitating close observation of kidney and liver functions and appropriate treatment. This medication should not be mixed with calcium-containing solutions or other intravenous drugs and must be administered only with the designated solution. After use, the injection needle and syringe should not be reused and must be disposed of in a safe container, out of reach of children.

Side effects

  • Gastritis
  • diarrhea
  • abdominal pain
  • dyspepsia
  • nausea
  • constipation
  • musculoskeletal pain
  • joint pain
  • muscle pain
  • influenza-like illness
Show 54 more
  • fatigue
  • headache
  • rash
  • bone pain
  • weakness
  • injection site reaction
  • phlebitis
  • thrombophlebitis
  • hypersensitivity reaction
  • angioedema
  • facial swelling
  • edema
  • urticaria
  • uveitis
  • episcleritis
  • scleritis
  • anaphylactic reaction
  • shock
  • asthma exacerbation
  • Stevens-Johnson syndrome
  • erythema multiforme
  • vesicular dermatitis
  • atypical pathologic fracture
  • subtrochanteric femoral fracture
  • external auditory canal osteonecrosis
  • jaw osteonecrosis
  • sensory loss
  • acute renal failure
  • dizziness
  • optic atrophy
  • lower motor neuron lesion
  • tremor
  • unspecified gastrointestinal disease
  • benign gastrointestinal neoplasm
  • dental pain
  • hyperventilation
  • cough
  • dyspnea
  • laryngitis
  • vaginitis
  • menopausal symptoms
  • multiple organ failure
  • death
  • insomnia
  • anxiety
  • tinnitus
  • hearing loss
  • hypothyroidism
  • lipoma
  • ocular hemorrhage
  • heart failure
  • urination disorders
  • hematuria
  • skin desquamation

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent exposure to air or moisture. Additionally, it is important to maintain a storage temperature between 1 to 30 degrees Celsius to preserve the effectiveness of the medication.

Appearance and packaging

Appearance

An injection in a colorless, transparent solution contained in a colorless, transparent glass prefilled syringe, accompanied by a single-use needle.

Package unit

3ml x 1 vial

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.